Company Overview of X-Chem, Inc.
X-Chem, Inc. operates as a subsidiary of Pharmaceutical Product Development Inc.
100 Beaver Street Suite 101
Waltham, MA 02453
Key Executives for X-Chem, Inc.
X-Chem, Inc. does not have any Key Executives recorded.
X-Chem, Inc. Key Developments
X-Chem, Inc. Enters into Licensing Agreement with Navitor Pharmaceuticals, Inc
Apr 1 15
X-Chem, Inc. has entered into a licensing agreement with Navitor Pharmaceuticals, Inc. for an exclusive license to a series of small molecules targeting the activation of mTORC1, a protein complex that orchestrates nutrient-mediated cellular metabolism and growth. The compounds licensed by Navitor were discovered by X-Chem screening their proprietary DEX platform against protein targets supplied by Navitor under a drug discovery agreement established by the parties in 2014. X-Chem has received research funding from Navitor upon initiation of the agreement and a license fee upon exercise of the license.
X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG
Dec 17 14
X-Chem, Inc. announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012. The latest program comprises several series of small molecule compounds against a cardiovascular drug target. Under the terms of this agreement, X-Chem will receive an upfront license fee in addition to payments based on the achievement of defined pre-clinical, clinical and sales milestones, as well as royalties. This license further validates the innovative nature of X-Chem’s team and approach.
X-Chem Signs Drug Discovery Collaboration with Alexion
Dec 15 14
X-Chem has signed drug discovery collaboration with Alexion. The contract has been signed for new therapies to treat patients with severe and ultra-rare disorders. According to the agreement, X-Chem will deploy its drug discovery engine, which is based on an ultra-large, high-diversity library in excess of 100 billion molecules, to identify new drug candidates against targets chosen by Alexion. The contract will see X-Chem receive an upfront payment and receive additional payments upon the achievement of specified research, development and regulatory milestones. X-Chem will also receive royalty payments on the sale of products resulting from the collaboration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries